Oy Medix Biochemica Ab
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Oy Medix Biochemica Ab - overview
Established
1985
Location
Espoo, -, Finland
Primary Industry
Biotechnology
About
Based in Espoo, Finland, and founded in 1985, Oy Medix Biochemica Ab, a. k. a. Medix Biochemica, operates as a as a global supplier of raw materials for in vitro diagnostics (IVD).
Minerva Capital Partners acquired Oy Medix Biochemica Ab. In September 2024, DevCo moved Oy Medix Biochemica Ab from DevCo II to the Devco Continuation Fund. Medix Biochemica's product portfolio includes antibodies, antigens, and enzymes critical for the development of diagnostic tests. These products are used across disciplines and disease areas, supporting markets in immunoassay, clinical chemistry, and molecular diagnostics.
The company also offers contract manufacturing and biospecimen accrual services, assisting customers in bringing their products to market faster. Medix Biochemica serves a variety of market segments, including immunoassay, clinical chemistry, and molecular diagnostics.
Current Investors
DevCo, Ilmarinen Mutual Pension Insurance Company, Rettig Group
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Diagnostic Equipment, Pharmaceutical Research & Development
Website
www.medixbiochemica.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Oy Medix Biochemica Ab - timeline of key events
Oy Medix Biochemica Ab - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 19,387,219.9 | 20,735,632.1 | 16,374,936.8 | 20,052,847.6 | 21,961,595.7 | - | - | - |
| % Revenue Growth (YoY) | - | 7.0% | (21.0%) | 22.5% | 9.5% | - | - | - |
| EBITDA (USD) | 6,843,509.6 | 7,545,610.7 | 7,307,150.2 | 8,039,734.5 | 8,703,691 | - | - | - |
| Operating Income (USD) | 5,998,883.2 | 6,654,943.8 | 6,559,679.2 | 6,898,354.4 | 7,177,382.9 | - | - | - |
| Operating Margin | 30.9% | 32.1% | 40.1% | 34.4% | 32.7% | - | - | - |
| % EBITDA Margin | 35.3% | 36.4% | 44.6% | 40.1% | 39.6% | - | - | - |
| NET Income (USD) | 4,842,586.5 | 5,395,641.6 | 5,069,160.1 | 3,733,888.7 | 5,505,828.3 | - | - | - |
| % Net Margin | 25.0% | 26.0% | 31.0% | 18.6% | 25.1% | - | - | - |
Oy Medix Biochemica Ab - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | CANDOR Bioscience GmbH | - | ||||||||
| Secondary Buyout | Completed | Oy Medix Biochemica Ab | - | ||||||||
| Add-on | Completed | ViroStat, Inc. | - | ||||||||
| Add-on | Completed | Bioresource Technology Inc. | - | ||||||||
| Add-on | Completed | MyPOLS Biotec GmbH | - |
Displaying 1 - 5 of 12
Oy Medix Biochemica Ab - employee data
Oy Medix Biochemica Ab - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chairman of board until April 2015, member of board until May 2016 | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.